2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 820

CC-220: A Clinical Stage Immunomodulatory, Antifibrotic Drug For Systemic Sclerosis
Abstract Number: 1642

CD25+CD39+ Regulatory T Cells Are Enriched At The Site Of Inflammation Of Patients With Rheumatoid Arthritis and Impaired In Suppressing IL-17A Secretion
Abstract Number: 2419

CDK6 Transcripts Expression Control By The Synoviocyte Proliferation Gene, SPACIA1
Abstract Number: L21

Celastrol, a Triterpene from Tripterygium Wilfordii, Inhibits Neutrophil Extracellular Trap Formation
Abstract Number: 1729

Cell Cycle Regulation Therapy Combined With Cytokine Blockade Enhances Anti-Arthritic Effects Without Increase Of Immune Suppression
Abstract Number: 730

Cell-Mediated Immune Responses To Influenza and Herpesvirus Antigen Stimulation Are Conserved But Adversely Impacted By Immunosuppressive Therapy and Active Infection In Patients With Granulomatosis With Polyangiitis
Abstract Number: 1847

Certolizumab-Pegol Induces Reverse Signaling Through Membrane TNF Via Calcineurin Activation In Human Monocytes. Relevance In Inflammation
Abstract Number: L12

Cetrorelix, a Gonadotropin-Releasing Hormone Antagonist, Demonstrates Efficacy and Significantly Reduces Proinflammatory Cytokines in Patients with Active Longstanding Rheumatoid Arthritis with High Gonadotropin Levels: A Proof-of-Concept, Double-Blind, Randomized Trial
Abstract Number: 1130

Change In Knee Osteophyte Volume By Semi-Automated Method In Knee Osteoarthritis Over Four Years Using 3T DESS 3D MRI
Abstract Number: 2387

Change of serum Amyloid a predict The Effect Of Biological Treatment In Rheumatoid Arthritis Patient
Abstract Number: 2458

Change Over Time In The Profile Of Ankylosing Spondylitis Patients Treated With Infliximab In Canadian Routine Care
Abstract Number: 416

Changes In Body Composition On Two Different Glucocorticoid Regimens In Early RA: Experience From The Cobra-Light Trial
Abstract Number: 950

Changes In Circulating Visfatin Levels By Different Anti-Rheumatic Treatments: A Comparison Among Synthetic Disease Modifying Anti-Rheumatic Drugs, Tumor Necrosis Factor Blockade and B-Cell Depletion For Rheumatoid Arthritis
Abstract Number: 1397

Changes In MMP In Fibroblast-Like Synoviocytes Following Adipogenesis
Abstract Number: 2869

Changes In Patient-Reported Joint Counts and Composite Indices Can Identify Flare Of Disease Activity In Recent Onset Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].